Neuroprotective profile of riluzole in in vivo models of acute neurodegenerative diseases

CNS Drug Reviews

Volumn 3, Issue 1, 1997, Pages 83-101

  Stutzmann, J M ^a,c   Wahl, F ^a   Pratt, J ^a   Mary, V ^a   Reibaud, M ^a   Tecoult, E ^b   Rataud, J ^a  

^a Neurodeg Dis Psychopharmacology D   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c SANOFI   (France)

Author keywords

Brain irradiation; Glutamate; Hypoxia; In vivo models; Ischemia; Na+ channel blockade; Neurotrauma; Riluzole

Indexed keywords

6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; APTIGANEL; DIZOCILPINE; LAMOTRIGINE; LUBELUZOLE; RILUZOLE;

ANIMAL MODEL; BRAIN HYPOXIA; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; NEUROPROTECTION; NONHUMAN; REVIEW; SPINAL CORD COMPRESSION; SPINAL CORD INJURY;

EID: 0030930499     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1997.tb00318.x     Document Type: Review

References (79)

1. Alaoui F, Pratt J, Trocherie S, Court L, Stutzmann JM. Acute effects of irradiation of the rat brain: Protection by glutamate blockade. Eur J Pharmacol 1995;276:55-60.
2. Aniksztejn L, Charriaut-Marlangue C, Roisin MP, Ben-Ari Y. Long-term potentiation in the rat hippocampus induced by the mast cell degranulating peptide: Analysis of the release of endogenous excitatory amino acids and proteins. Neuroscience 1990;35:63.
3. Bassant MH, Court L. Effects of whole body gamma irradiation on the activity of rabbit hippocampal neurons. Radiat Res 1978;75:593-606.
4. Bath PMW. Treating acute ischemic stroke. Br Med J 1995;311:139-140.
5. Benavides J, Camelin JC, Mitrani N, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. II. Biochemical properties. Neuropharmacology 1985;24:1085-1092.
6. + channels in myelinated nerve fibre. Pflüger's Arch 1991;419:603-609.
7. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
8. Browne SE, McCulloch J. AMPA receptor antagonists and local cerebral glucose utilization in the rat. Brain Res 1994;641:10-20.
9. Chéramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209-212.
10. Choi DW. Glutamate neurotoxicity and diseases of the central nervous system. Neuron 1988;1:623-634.
11. Collins GS. Some effects of excitatory amino acid receptor antagonists on synaptic transmission in the rat olfactory cortex slice. Brain Res 1982;244:311-318.
12. Davies SM, Albers GW, Diener H-C, Lees KR, Norris J. Termination of acute stroke studies involving sclfotel treatment. Lancet 1997;349:32.
13. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders. DN&P 1995;8:261-277.
14. Debono MW, Le Guern J, Canton T, et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
15. Demeyer I, Luther RR, Verhoeven FJS. SNX-111 in severe head injury: Preliminary results. Abstracts of the 6th International Symposium on Pharmacology of Cerebral Ischemia 1996:94.
16. Diener HC, Hacke W, Hennerici M, et al. Lubeluzole in the acute treatment of ischemic stroke: Results of phase-2 trial. J Cereb Blood Flow Metab (Suppl) 1995;15:S128.
17. Diener HC, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Stroke 1996:27:76-81.
18. 3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992;140:251-254.
19. Doble A, Perrier ML. Pharmacology of excitatory amino acid receptors coupled to inositol phosphate metabolism in neonatal rat striatum. Neurochem Int 1989;15:1-8.
20. Estevez A, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur J Pharmacol 1995;280:47-53.
21. Fix AS, Long GG, Wozniak DF, Olney JW. Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: A review. Drug Dev Res 1994;32:147-152.
22. Gamzu ER. Update on cerestat clinical development. In: IBC, ed. Recent Advances in the Understanding, Therapy and Diagnosis of Ischemic Stroke. Southborough: IBC Inc, 1996.
23. Gill R, Lodge D. The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischemia. Neuropharmacology 1994;33:1529-1536.
24. Girdlestone D, Dupuy A, Coston A, et al. D. Riluzole antagonizes excitatory amino acid-evoked firing in rat facial motoneurons in vivo. Br J Pharmacol (Suppl 583P) 1989;97.
25. Greifenstein FE, DeVault M, Yoshitake J, Gajewski JE. A study of 1-aryl cyclohexylamine for anesthesia. Anesth Analg 1959;31:433-439.
26. Gueneau G, Privat A, Drouet J, Court L. Subgranular zone of the dentate gyms of young rabbits as a secondary matrix. Develop Neurosci 1982;5:345-358.
27. Hacke W, Niedermaier N, Wildemann B. Thrombolytic therapy in acute ischemic stroke - an update. In: Krieglstein J, ed. Pharmacology of Cerebral Ischemia. Boca Raton: CRC Press, 1994;617-623.
28. Hall E, Althaus J, Von Voigtlander P. Lazaroids: Neuroprotective antioxidant mechanisms. Can J Physiol Pharmacol (Suppl 1) 1994;72:S26.3.
29. Hall ED. High glucose treatment improves neurological recovery in head-injury mice. J Neurosurg 1995;62:882-887.
30. Heros RC. Stroke: Early pathophysiology and treatment. Stroke 1994;25:1877-1881.
31. Hommel M, Bogousslavsky J. Thrombolytics in acute cerebral ischemia. Exp Opin Invest Drugs 1994;3:1011-1020.
32. Johnstone M, Evans V, Baigel S. Sernyl (CI-395) in clinical anesthesia. Br J Anaesth 1959;96:25-135.
33. Kligerman MM, Turrisi AT, Urtasun RC, et al. Final report on phase 1 trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:1119-1122.
34. Kraus JF. Overview in epidemiology of traumatic brain injury. Abstracts 1st World Congress on Brain Injury 1995;5.
35. Lacomblez L, Bensimon G, Nigel Leigh P, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
36. Lea TJ, Ashley CC. Harmaline distribution in single muscle fibres and the inhibition of sodium efflux. Biochim Biophys Acta 1981;664:74-81.
37. Leach MJ, Swan JH, Eisenthal D, et al. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993;24:1063-I067.
38. Lees KR. Therapeutic interventions in acute stroke. Br J Clin Pharmacol 1992;34:486-493.
39. MacCown TJ, Givens BS, Breese GR. Amino acid influences on seizures elicited within the inferior colliculus. J Pharmacol Exp Ther 1987;243:603-608.
40. MacCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. Br J Clin Pharmacol 1992;34:106-114.
41. Mackay KB, Kusumoto K, Graham DI, MacCulloch J. Effect of the kappa-1 opioid agonist CI-977 on ischemic brain damage and cerebral blood flow after middle cerebral artery occlusion in the rat. Brain Res 1993;629:10-18.
42. Malgouris C, Bardot F, Daniel M, et al. Riluzole, a novel anti-glutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989;9:3720-3727.
43. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of L-glutamate and L-aspartate from slices of hippocampal area CA1. Dr J Pharmacol (Suppl) 1991;104:240P.
44. McIntosh TK, Voddi M, Smith D, Stutzmann JM. Riluzole, a compound which interferes with glutamate neurotransmission, improves cognitive deficit following experimental brain injury in rats. J Neurotrauma 1995;12:379.
45. McIntosh TK, Smith DH, Voddi M, Perri BR, Stutzmann JM. Riluzole, a novel neuroprotective agent, attenuates both neurological motor and cognitive dysfunction following traumatic brain injury in the rat. J Neurotrauma 1996;13:767-780.
46. Meldrum BS, Chapman AG. Excitatory amino acids and anticonvulsant drug action. In: Hertz L, Kvamme E, McGeer E, Schousboe A, eds. Glutamine, Glutamate and GABA in the Central Nervous System. New York: Alan R. Liss, 1983:625-642.
47. Meldrum BS. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci 1985;68:113-122.
48. Meldrum BS, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
49. Meldrum DS. Amino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disorders. Brain Res Rev 1993;18:293-314.
50. Millan MH, Chapman AG, Meldrum BS. Dual inhibitory action of enadoline (CI 977) on release of amino acids in the rat hippocampus. Eur J Pharmacol 1995;279:75-81.
51. Mizoule J, Meldrum B. Mazadier M, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 1985;24:767-773.
52. Mottet I, Demeure R, Lucas M, et al. Neuroprotective effect of intravenous administration of Riluzole in focal cerebral ischemia in rats: Follow-up of the lesion development by magnetic resonance imaging 1997 (submitted).
53. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-513.
54. Olney JW, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity mechanism and prevention. Science 1991;254:1515-1518.
55. Osikowska-Evers BA, Wihelm D, Nebel U, et al. The effects of the novel neuroprotective compound lubeluzole on sodium current and veratridine induced sodium load in rat brain neurons and synaptosomes. J Cereb Blood Flow Metab (Suppl) 1995:15:8380.
56. Pratt J, Rataud J, Bardot F, et al. Neuroprotective action of riluzole in rodent models of global and focal cerebral ischemia. Neurosci Lett 1992;140:251-254.
57. Rataud J, Malgouris C, Bardot F, et al. Neuronal protection by riluzole against ischemic brain damage in gerbils. In: Krieglstein J, ed. Pharmacology of Cerebral Ischemia. Boca Raton: CRC Press, 1988:261-264.
58. R & D focus. 1995;4:8.
59. R & D focus. 1996;5:6.
60. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-111.
61. Sandercock P, Willems H. Medical treatment of acute ischemic stroke. Lancet 1992;339:537-539.
62. Scatton B, Benavides J, Carter C, et al. The NMDA macromolecular complex as a target for the development of anti-ischemic drugs. Clin Neuropharmacol 1992;15:S133-437.
63. Scheller D, Kolb J, Szathmary S, Zacharias E, et al. Extracellular changes of glutamate in the periinfarct zone. Effect of lubeluzole. J Cereb Blood Flow Metab (Suppl) 1995;15:S379.
64. Sila CA. Prophylaxis and treatment of stroke. Drugs 1993;45:329-337.
65. Smith SE, Lekieffre D, Sowinski P, Meldrum BS. Cerebroprotectivc effect of BW619C89 after focal or global cerebral ischemia in the rat. Neuroreport 1993;4:1339-1342.
66. + channels. Abstr Am Soc Neurosci 1996;22:33-32.
67. Strategies in stroke treatment and prophylaxis. Pharma Projects. Executive Briefing. February 1995;25-29.
68. Stutzmann JM, Böhme GA, Gandolfo G, ct al. Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dentrotoxin 1 in the rat. Eur J Pharmacol 1991;193-223.
69. Stutzmann JM, Pratt J, Boraud T, Gross C. Riluzole's Effect on post-traumatic spinal cord injury in the rat. Neuroreport 1996;7(2):387-392.
70. Stutzmann JM, Doble A. Blockade of glutaminergic transmission and neuroprotection: The strange case of riluzole. In: Jolles G, Stutzmann JM, eds. Neurodegeneratice Disease. New York: Academic Press, 1994;205-214.
71. Sun FY, Faden AI. Neuroprotective effects of 619C89, a use-dependent sodium channel blocker, in rat traumatic brain injury. Brain Res 1995;673:133-140.
72. Tamura A, Graham DI, MacCulloch J, Teasdale GM. Focal cerebral ischemia in the rat: I. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1981;1:53-60.
73. Taylor C, Tsai C, Lehmann J. Sodium fluxes modulating neuronal glutamate uptake: Differential effects of local anesthetic and anticonvulsant drugs. J Pharmacol Exp Ther 1988;244:666-673.
74. Taylor CP, Vartanian MG. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. Em J Phannacol 1992;213:151-153.
75. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992;23:3-8.
76. Turkel CC. Is stroke penumbra the victim of lactate neurotoxicity. In: IBC, ed. Recent Advances in the Understanding, Therapy and Diagnosis of Ischemia Stroke. Southborough: IBC Inc, 1996.
77. Wahl F, Allix M, Plotkine M, Boulu RG. Effects of riluzole on focal cerebral ischemia in rats. Eur J Phannacol 1993:230:209-214.
78. Wauquier A, Ashton D, Clincke G, Niemegeers CJE. Anti-hypoxic effects of etomidate, thiopental and methohexital. Arch Int Pharmacodyn Ther 1981;249:330-334.
79. Yum SW, Saden AI. Comparison of the neuroprotective effects of N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 1990;47:277-281.